(Q27690919)

Marshall CB

series ordinal

2

1 reference

American Journal of Clinical Pathology

language of work or name

English

1 reference

inferred from

publication date

September 2012

1 reference

American Journal of Clinical Pathology

published in

1 reference

volume

138

1 reference

issue

3

1 reference

page(s)

332-46

1 reference

Non–Small Cell Lung Cancer

cites work

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Molecular testing in lung cancer: the time is now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Laboratory methods for KRAS mutation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

The role of cytology specimens in molecular testing of solid tumors: techniques, limitations, and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Changes in smoking prevalence among U.S. adults by state and region: Estimates from the Tobacco Use Supplement to the Current Population Survey, 1992-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Lung cancer in never smokers: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Lung cancer in never smokers--a different disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Screening for lung cancer: a review of the current literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Reduced lung-cancer mortality with low-dose computed tomographic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Benefits and harms of CT screening for lung cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

The evolving role of histology in the management of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Analysis of ErbB receptors in pulmonary carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

KRAS mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Respiratory cytology in the era of molecular diagnostics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Chipping away at the lung cancer genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Emerging new agents for the management of patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Novel therapeutic targets in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCPFR12WJKCEEZZ

21 January 2018

Identifiers

DOI

10.1309/AJCPFR12WJKCEEZZ

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22912349

1 reference

Consolidated OpenCitations Corpus – April 2017